PharVision Advisers’s Stepan Co SCL Stock Holding History

PharVision Advisers’s Portfolio SCL Stock Details SCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,203	Closed	-$294K	–	547
2025 Q4	$294K	Buy	6,203 +1,357	+28%	+$62.1K	0.15%	284
2025 Q3	$231K	Buy	+4,846	New	+$251K	0.13%	389

Other funds holding SCL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

DRZID

DePrince Race & Zollo Inc (DRZ) Winter Park, Florida $5.96B AUM 38.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

PharVision Advisers's SCL Position: Q1 2026 in Review

PharVision Advisers sold out of Stepan Co (SCL) in Q1 2026, closing a stake of 6,203 shares — an estimated $294K sold.

PharVision Advisers first reported a position in SCL in Q3 2025 and held it in 2 quarters. The position peaked at $294K in Q4 2025. 224 funds tracked by Wall St. Rank hold SCL as of Q1 2026.

PharVision Advisers reported no remaining Stepan Co position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 6,203 Stepan Co shares in Q1 2026, an estimated $294K.
PharVision Advisers first reported a position in Stepan Co in Q3 2025 and held it in 2 quarters.
PharVision Advisers's Stepan Co position peaked at $294K in Q4 2025.
224 funds tracked by Wall St. Rank held Stepan Co as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.